Graham Anderson of Kenect : 89 Percent of Consumers Prefer Text to Phone Call

 

Even though texting has become a staple of how we communicate, businesses are still scared to use it to interact with customers. They shouldn’t be, though; it’s way more powerful than any other medium out there. 95 percent of all text messages arrive within three minutes and are opened soon thereafter, but less than 20 percent of emails are even opened. Imagine that communicative power blasting customers’ cell phones.

In this podcast, we speak with Graham Anderson, Chief Marketing Officer for Kenect, about how texting is revolutionizing the way that businesses are now communicating with their customers and potential customers.

Businesses are tentative to text, but study after study shows that consumers actually want businesses to shoot their shot over text. 89 percent of consumers would rather interact via text messaging than with a phone call, for a variety of reasons: they don’t like to wait on hold (and can become annoyed with a business after sitting on hold too long), they don’t like being called at an inconvenient time and it’s a hassle to play phone tag.

Anderson paints a vivid scenario, one that he says is attainable: instead of waiting two or three days for a doctor’s office to call back or waiting 20 minutes on hold, an employee could just text a client with an appointment time and they could reply back confirming or denying, saving everyone a lot of valuable time and energy. They could even send back a calendar link so all the available appointments could be browsed.

Listen to Anderson explain how businesses can leverage text messaging to make sure that customers respond to survey requests and even invoices more than 30 times the average of traditional attempts, as well as how businesses are actually selling directly through text messaging, which according to Anderson, is pure gold and a win for everyone.

For the latest news, videos, and podcasts in the Retail Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @RetailMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More